74 | A MULTICENTER PHASE II STUDY OF GLOFITAMAB PLUS POLATUZUMAB‐R‐CHP FOR PATIENTS WITH HIGH‐RISK DIFFUSE LARGE B‐CELL LYMPHOMAJennifer L. Crombie, Juan Pablo Alderuccio, Sandra Re et al.|Hematological Oncology|2025Cited by 3
227 | RITUXIMAB AND EPCORITAMAB AS FIRST‐LINE THERAPY FOR PATIENTS WITH HIGH‐TUMOR BURDEN FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIALR. Merryman, Yazeed Sawalha, D. S. Wallace et al.|Hematological Oncology|2025Cited by 1